DUBLIN–(BUSINESS WIRE)–The “Meningitis – Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report provides an overview of the Meningitis (Infectious Disease) pipeline landscape.
Researchers have identified 13 major serogroups of N. meningitides, out of which the majority of cases are from one of five serogroups: A, B, C, Y and W-135. Drugs and vaccines are available to treat the serogroups AC, C, ACWY, and A. There are also vaccines available to prevent meningitis caused by serogroups A, C, Y, W-135. There are no vaccines or drugs available for the prevention and treatment of meningococcal meningitis caused by serogroup B.
This represents a major unmet need in the market. Pneumococcal meningitis is another major bacterial cause of meningitis, caused by the bacteria streptococcus pneumonia, while haemophilius influenza is the third, and causes meningitis in infants. Approximatiely 44-46% cases of bacterial meningitis have all of the following three symptoms – severe headache, nuchal ridgidity ((inability to flex the neck forward passively due to increased neck muscle tone and stiffness) and altered mental status. Out of this triad of symptoms severe headache is the most common and occurs in 90% of the cases. If nove of the above mentioned symptoms are present, then occurrence of bacterial meningitis is least likely. Other clinical features include photophobia (fear of bright light) and phonophobia (fear of loud noises). In small children the symptoms are difficult to spot. Vague symptoms like irritability and unwell appearance are more common in them. In infants up to 6 months, bulging of the fontanelle (soft spot on baby’s head) may be visible. (Read more…) Other less severe illnesses like extreme cold, abnormality in skin color and leg pain may also be distinguishing features for meningitis.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Meningitis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Meningitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
- Introduction
- Report Coverage
- Meningitis – Overview
- Meningitis – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Meningitis – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Meningitis – Companies Involved in Therapeutics Development
- CanSino Biologics Inc
- Chongqing Zhifei Biological Products Co Ltd
- Eubiologics Co Ltd
- FUJIFILM Toyama Chemical Co Ltd
- Liaoning Cheng Da Biotechnology Co Ltd
- Linnaeus Bioscience Inc
- Matinas BioPharma Holdings Inc
- Mycovia Pharmaceuticals Inc
- Olymvax Biopharmaceuticals Inc
- Pneumagen Ltd
- TGV Therapeutics
- Yisheng Biopharma Co Ltd
- Meningitis – Drug Profiles
- Meningitis – Dormant Projects
- Meningitis – Discontinued Products
- Meningitis – Product Development Milestones
- Featured News & Press Releases
- Appendix
Companies Mentioned
- CanSino Biologics Inc
- Chongqing Zhifei Biological Products Co Ltd
- Eubiologics Co Ltd
- FUJIFILM Toyama Chemical Co Ltd
- Liaoning Cheng Da Biotechnology Co Ltd
- Linnaeus Bioscience Inc
- Matinas BioPharma Holdings Inc
- Mycovia Pharmaceuticals Inc
- Olymvax Biopharmaceuticals Inc
- Pneumagen Ltd
- TGV Therapeutics
- Yisheng Biopharma Co Ltd
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/jtkgb6
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900